Top

Published in:

01-03-2016 | Topic Review

Immunomonitoring in glioma immunotherapy: current status and future perspectives

Authors: Jonathan B. Lamano, Leonel Ampie, Winward Choy, Kartik Kesavabhotla, Joseph D. DiDomenico, Daniel E. Oyon, Andrew T. Parsa, Orin Bloch

Published in: Journal of Neuro-Oncology | Issue 1/2016

Abstract

Given the continued poor clinical outcomes and refractory nature of glioblastoma multiforme to traditional interventions, immunotherapy is gaining traction due to its potential for specific tumor-targeting and long-term antitumor protective surveillance. Currently, development of glioma immunotherapy relies on overall survival as an endpoint in clinical trials. However, the identification of surrogate immunologic biomarkers can accelerate the development of successful immunotherapeutic strategies. Immunomonitoring techniques possess the potential to elucidate immunological mechanisms of antitumor responses, monitor disease progression, evaluate therapeutic effect, identify candidates for immunotherapy, and serve as prognostic markers of clinical outcome. Current immunomonitoring assays assess delayed-type hypersensitivity, T cell proliferation, cytotoxic T-lymphocyte function, cytokine secretion profiles, antibody titers, and lymphocyte phenotypes. Yet, no single immunomonitoring technique can reliably predict outcomes, relegating immunological markers to exploratory endpoints. In response, the most recent immunomonitoring assays are incorporating emerging technologies and novel analysis techniques to approach the goal of identifying a competent immunological biomarker which predicts therapy responsiveness and clinical outcome. This review addresses the current status of immunomonitoring in glioma vaccine clinical trials with emphasis on correlations with clinical response.

Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Keilholz U, Martus P, Scheibenbogen C (2006) Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 12:2346s–2352sCrossRefPubMed

Yamanaka R, Homma J, Yajima N et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160–4167CrossRefPubMed

Clavreul A, Piard N, Tanguy J-Y et al (2010) Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. J Clin Neurosci 17:842–848CrossRefPubMed

Sampson JH, Heimberger AB, Archer GE et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729PubMedCentralCrossRefPubMed

Sloan AE, Dansey R, Zamorano L et al (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9:1–8CrossRef

Muragaki Y, Maruyama T, Iseki H et al (2011) Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma: clinical article. J Neurosurg 115:248–255CrossRefPubMed

Ishikawa E, Muragaki Y, Yamamoto T et al (2014) Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma: clinical article. J Neurosurg 121:543–553CrossRefPubMed

Steiner HH, Bonsanto MM, Beckhove P et al (2004) Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22:4272–4281CrossRefPubMed

10.

Yamanaka R, Abe T, Yajima N et al (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172–1179PubMedCentralCrossRefPubMed

11.

Rutkowski S, De Vleeschouwer S, Kaempgen E et al (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656–1662PubMedCentralPubMed

12.

Vik-Mo EO, Nyakas M, Mikkelsen BV et al (2013) Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 62:1499–1509PubMedCentralCrossRefPubMed

13.

Ardon H, Van Gool S, Lopes IS et al (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99:261–272CrossRefPubMed

14.

Ishikawa E, Tsuboi K, Yamamoto T et al (2007) Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 98:1226–1233CrossRefPubMed

15.

Fadul CE, Fisher JL, Hampton TH et al (2011) Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 34:382PubMedCentralCrossRefPubMed

16.

Yajima N, Yamanaka R, Mine T et al (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11:5900–5911CrossRefPubMed

17.

De Vleeschouwer S, Fieuws S, Rutkowski S et al (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098–3104CrossRefPubMed

18.

Wheeler CJ, Black KL, Liu G et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955–5964CrossRefPubMed

19.

Akiyama Y, Oshita C, Kume A et al (2012) α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer 12:623PubMedCentralCrossRefPubMed

20.

de Vries IJM, Bernsen MR, Lesterhuis WJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779–5787CrossRefPubMed

21.

Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7:1127–1135PubMed

22.

Piguet PF, Vassalli P (1973) Study of the thymic-derived or-independent nature of mouse spleen cells induced to proliferate in culture by various mitogens and antigens. Eur J Immunol 3:477–483CrossRefPubMed

23.

Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171:131–137CrossRefPubMed

24.

Crane CA, Han SJ, Ahn B et al (2013) Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 19:205–214CrossRefPubMed

25.

Soares A, Govender L, Hughes J et al (2010) Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods 362:43–50PubMedCentralCrossRefPubMed

26.

Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM (1998) Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol 16:743–747CrossRefPubMed

27.

Brunner K, Mauel J, Cerottini J-C, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells of 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181PubMedCentralPubMed

28.

Matzinger P (1991) The JAM test A simple assay for DNA fragmentation and cell death. J Immunol Methods 145:185–192CrossRefPubMed

29.

Kikuchi T, Akasaki Y, Abe T et al (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452–459CrossRefPubMed

30.

Yu JS, Wheeler CJ, Zeltzer PM et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847PubMed

31.

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979CrossRefPubMed

32.

Nociari MM, Shalev A, Benias P, Russo C (1998) A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 213:157–167CrossRefPubMed

33.

Liu L, Chahroudi A, Silvestri G et al (2002) Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 8:185–189CrossRefPubMed

34.

Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C (1995) A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184:39–51CrossRefPubMed

35.

Schmid I, Krall WJ, Uittenbogaart CH, Braun J, Giorgi JV (1992) Dead cell discrimination with 7-amino-actinomcin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 13:204–208CrossRefPubMed

36.

Betts MR, Brenchley JM, Price DA et al (2003) Sensitive and viable identification of antigen-specific CD8⁺ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78CrossRefPubMed

37.

Liau LM, Prins RM, Kiertscher SM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525CrossRefPubMed

38.

Phuphanich S, Wheeler CJ, Rudnick JD et al (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135PubMedCentralCrossRefPubMed

39.

Engvall E, Perlmann P (1971) Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochemistry 8:871–874CrossRefPubMed

40.

Czerkinsky CC, Nilsson L-Å, Nygren H, Ouchterlony Ö, Tarkowski A (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65:109–121CrossRefPubMed

41.

Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197–207CrossRefPubMed

42.

Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. Genome Res 6:986–994CrossRefPubMed

43.

Pellegatta S, Eoli M, Frigerio S et al (2013) The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2:e23401PubMedCentralCrossRefPubMed

44.

Olin MR, Low W, McKenna DH et al (2014) Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4⁺ IL17⁺ response. J Immunother Cancer 2:1–11CrossRef

45.

Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344CrossRefPubMed

46.

Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z (2012) Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys 62:91–99CrossRefPubMed

47.

Okada H, Lieberman FS, Walter KA et al (2007) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5:67PubMedCentralCrossRefPubMed

48.

Iwami K, Shimato S, Ohno M et al (2012) Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A* 24/A* 02 allele. Cytotherapy 14:733–742CrossRefPubMed

49.

Schuster J, Lai RK, Recht LD, et al. (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-oncology:nou348

50.

Bloch O, Crane CA, Fuks Y et al (2014) Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-oncology 16:274–279PubMedCentralCrossRefPubMed

51.

Ardon H, Van Gool SW, Verschuere T et al (2012) Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61:2033–2044CrossRefPubMed

52.

Prins RM, Wang X, Soto H et al (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother (Hagerstown, Md: 1997) 36:152

53.

Fong B, Jin R, Wang X et al (2012) Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS ONE 7:e32614PubMedCentralCrossRefPubMed

54.

Prins RM, Soto H, Konkankit V et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615PubMedCentralCrossRefPubMed

55.

Perez OD, Nolan GP (2002) Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 20:155–162CrossRefPubMed

56.

Bendall SC, Simonds EF, Qiu P et al (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332:687–696PubMedCentralCrossRefPubMed

57.

Everson RG, Jin RM, Wang X et al (2014) Cytokine responsiveness of CD8 (+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2:10PubMedCentralCrossRefPubMed

58.

Chang S, Kohrt H, Maecker HT (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713–719PubMedCentralCrossRefPubMed

59.

Gustafson MP, Lin Y, LaPlant B et al (2013) Immune monitoring using the predictive power of immune profiles. J Immuno Ther Cancer 1:7–18CrossRef

60.

Qiu P, Simonds EF, Bendall SC et al (2011) Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 29:886–891PubMedCentralCrossRefPubMed

61.

E-aD Amir, Davis KL, Tadmor MD et al (2013) viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 31:545–552CrossRef

62.

Lesokhin AM, Callahan MK, Postow MA, Wolchok JD (2015) On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 7:280sr281CrossRef

63.

Ku GY, Yuan J, Page DB et al (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116:1767–1775PubMedCentralCrossRefPubMed

64.

Berman DM, Wolchok JD, Weber J, Hamid O, O’Day S, Chasalow SD (2009) Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 27:abstract 3020

65.

Simeone E, Gentilcore G, Giannarelli D et al (2014) Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63:675–683CrossRefPubMed

66.

Postow MA, Chasalow SD, Yuan J, et al (2013) Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. J Clin Oncol 31:abstract 9052

67.

Carthon BC, Wolchok JD, Yuan J et al (2010) Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16:2861–2871PubMedCentralCrossRefPubMed

68.

Nduom EK, Wei J, Yaghi NK, et al (2015) PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol

69.

Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330CrossRefPubMed

70.

Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199PubMedCentralCrossRefPubMed

71.

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520CrossRefPubMed

72.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128CrossRefPubMed

73.

Butterfield LH, Palucka AK, Britten CM et al (2011) Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 17:3064–3076PubMedCentralCrossRefPubMed

74.

Janetzki S, Britten CM, Kalos M et al (2009) “MIATA”-minimal information about T cell assays. Immunity 31:527–528PubMedCentralCrossRefPubMed

Title: Immunomonitoring in glioma immunotherapy: current status and future perspectives
Authors: Jonathan B. Lamano
Leonel Ampie
Winward Choy
Kartik Kesavabhotla
Joseph D. DiDomenico
Daniel E. Oyon
Andrew T. Parsa
Orin Bloch
Publication date: 01-03-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-2018-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunomonitoring in glioma immunotherapy: current status and future perspectives

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Primary Burkitt lymphoma of the fourth ventricle mimicking a medulloblastoma in a child

The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma

Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial

Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas

Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response

Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients